Background: Skin care remains a key component in atopic dermatitis (AD) management; there are no data available guiding optimal bathing recommendations.
E ducating patients and families on proper skin care remains a key component in atopic dermatitis (AD) management. Published treatment guidelines for the management of AD recommend the use of gentle cleansers and the frequent application of emollients. 1, 2 Surprisingly, there are virtually no data available to guide recommendations on optimal bathing practices. Some sources recommend daily bathing for patients with AD, whereas others, especially in the pediatric realm, recommend limiting baths to once or twice weekly. 3 Bathing practices are likely to significantly influence disease management in AD. On one hand, prolonged or repetitive contact with water can harm the skin barrier, theoretically worsening the disease. 4, 5 Conversely, water contact may be beneficial by hydrating the stratum corneum, allowing for enhanced stratum corneum uptake of topical corticosteroids (TCSs). 6 In our practice, we have long used bathing for 15 to 20 minutes followed by TCS application as a method for inducing clearance of even the most severe disease during the initial patient visits. 7 Patients are instructed to apply the ointment within 3 minutes of getting out of the bath tub after a brief ''pat dry.''Although 2 studies have shown that this ''soak and smear'' method may have utility in a variety of dermatoses, this technique has not been systematically evaluated in a population of patients with AD. 7Y11 The objective of the current study was to determine the effectiveness of the prehydration technique combined with topical steroid therapy in achieving disease control in patients with moderate to severe AD.
METHODS
After receiving institutional review board approval, we performed a retrospective review of the electronic health records of patients attending the outpatient dermatology clinic at the Oregon Health & Science University between January 1, 2007 and December 31, 2011. We identified patients using the International Classification of Diseases, Ninth Revision code of 691.8 (atopic and other eczematous conditions) and applied the following inclusion and exclusion criteria that were determined a priori:
Inclusion Criteria
1. The first visit must have been the initial visit to the Department of Dermatology.
2. Disease severity is described as moderate or severe in the assessment. Our practitioners routinely include an Investigators' Global Assessment (IGA) as part of the patient's initial evaluation, defined as a subjective determination taking into account the patient's severity of the skin disease, extent, and the quality of life impact. 3. Bathing for 15 to 20 minutes followed immediately by TCS must have been prescribed at least daily. A detailed representative regimen is shown in Table 1 . 4. A follow-up visit must have been scheduled within 1 to 3 weeks after the initial appointment.
Exclusion Criteria
1. The IGA was rated as mild at baseline visit. 2. The patient was treated with systemic therapies or phototherapy within 2 months of their initial visit. This criterion reduced the potential confounding effects of concomitant systemic therapies. 3. Patients carried a diagnosis of AD that was unclear or did not meet the diagnostic criteria for AD.
Outcomes
The primary outcome was the IGA at the first follow-up visit after the initiation of prehydration therapy. In cases where the provider did not record the IGA, an IGA was extrapolated using a combination of the patient report of disease activity and the physical examination.
Secondary Outcomes
A dynamic scale (Treatment Response Scale) was created to reflect both the patient's and the provider's assessment of treatment response compared with the baseline. Comments regarding the treatment response made by the patient or the provider were recorded as the following categories: worse, no improvement, moderate improvement, marked improvement, or complete clearing.
Data regarding patient demographics, disease course, and previous treatments were also extracted.
RESULTS
A search for the International Classification of Diseases, Ninth Revision code 691.8 produced a total of 110 distinct electronic records. Thirty-five patients were excluded for the following reasons: recent systemic therapy (11) or ultraviolet light (4) prescribed by referring physicians, mild disease (6), did not soak in a bath (2), did not satisfy the criteria for AD (12) , and had no follow-up appointment within the 3-week time frame (11) . A total of 75 patients were identified as meeting the criteria (Table 1 ). Although 11 patients had only a phone follow-up assessment, these patients were given a Treatment Response Scale score based on the patient's assessment of treatment response and were not given an IGA score because of the lack of an objective evaluation.
Demographics
Both pediatric and adult patients were represented in our sample ( Table 2) , and most patients had a history of asthma, food allergies, or allergic rhinitis (Table 3) . Among the 75 patients, 40 (53%) were female. The number of days between the baseline visit and the follow-up visit ranged from 2 to 21 days, with 36 patients (48%) assessed within 1 week, 32 (43%) within 2 weeks, and 7 (9%) within 3 weeks after the baseline visit. When evaluating the patients' eczema history, 70 (95%) had onset in childhood, and 4 (5%) had adult onset (onset was not available in 1 patient).
Previous Therapy
Most patients reported the use of low-potency, mid-potency, and high-potency TCS in the past. Patients also reported the use of topical 
Baseline Visit
At the initial visit, 48 patients (64%) had an IGA of severe, and 27 (36%) had moderate disease. All subjects were instructed to begin prehydration therapy (tub bath for 15Y20 minutes) followed by TCS. Mid-potency TCS preparations were prescribed in 49 patients (65%) (mainly triamcinolone acetonide 0.1% ointment), whereas 26 (35%) were prescribed high-potency TCS (mainly betamethasone diproprionate 0.05% ointment). Twenty-six patients (35%) also received an oral antibiotic (dicloxacillin or cephalexin) for 5 days. We had no documented evidence of bleach bath recommendations in the initial visit of any of the patients included in this study. The use of bleach baths is not a component of our routine clearance protocol.
Follow-up Visit
At the follow-up visit, 64 patients (85%) were evaluated with an IGA. The remaining 11 patients were only evaluated with the Treatment Response Scale by phone. No patients persisted with severe disease. Forty-seven patients (73%) were rated as almost clear, and 1 (2%) was clear ( Table 5 ). Thirteen patients (20%) had mild disease by IGA, and 3 (5%) had moderate disease. Using the patient's or provider's assessment of treatment response, 59 patients (79%) had marked improvement, and 3 patients (4%) were clear. Ten patients (13%) noted moderate improvement, and 3 (4%) had only slight improvement. No patients had worsened or reported no improvement ( Table 6) .
We further explored the responses of patients who had a history of systemic corticosteroid therapy (oral or intramuscular). Nearly all of these patients (93%) had severe disease when evaluated at the initial visit (IGA). At follow-up, 11 patients (73.3%) experienced marked improvement, 2 (13.3%) had moderate improvement, and 2 (13.3%) had only slight improvement.
Finally, to control for the possible effects that antibiotics may have had on the improvement seen, we stratified our results by those receiving antibiotics versus those who did not and found similar responses in both groups (IGA who were mild, almost clear or clear: 94.7% in the antibiotic group versus 95% in the nonantibiotic group).
DISCUSSION
Our retrospective study found very high response rates to prehydration followed by TCS application in both pediatric and adult patients with moderate to severe AD. Almost all (95%) achieved an IGA of at least mild after 1 to 2 weeks of prehydrating baths followed immediately by TCS therapy. These results are striking, especially in light of the fact that many patients had been previously treated with superpotent TCS or systemic therapy. The patients' perceptions of response agreed with the investigator's assessments with 83% of patients noting that they experienced at least marked improvement.
There are several potential reasons why such excellent outcomes were achieved with prehydration therapy. The most likely reason is the improved cutaneous uptake of TCS. Water has been considered the most natural and biocompatible penetration enhancer for improving skin permeability. 12 In 1954, Rothman 13 recognized that skin hydration enhanced the percutaneous absorption. In 1963, Cronin and colleagues found that hydration increased the penetration of ethyl nicotinate by 6-fold. 6 Stoughton 6 demonstrated 10-fold greater glucocorticoid permeability when the skin was hydrated. In addition, presoaking with warm water enhanced the reservoir effect by 5-fold for TCSs. 14 Other potential explanations for our results include the debriding effects of the bath and the improved adherence to the regimen. Bathing may reduce the concentration of bacteria on the skin while removing irritants and allergens. Patient adherence may be improved by treatment success and short follow-up time. Patients frequently diminish adherence after 1 to 2 weeks of treatment, but studies show that an intensive short course of outpatient treatment promotes good adherence and provides a high level of efficacy in patients with AD. 15, 16 Another study found that follow-up visits occurring within 1 week improved the adherence and treatment outcomes compared with a 4-week follow-up visit. 15, 16 Limitations of this study include its retrospective design and the lack of a validated objective grading scale for determining the severity and degree of improvement. The improvement seen in these patients could also represent the natural course of the disease or regression toward the mean, but in our experience, patients with moderate to severe AD rarely improve in 1 to 2 weeks without an intensive intervention. Although the study examines a useful technique for disease clearance, it did not address the optimum regimen for maintenance therapy. The prehydration technique is time-consuming, and it is not always safe for long-term use. Daily intensive use of TCS can lead to hypothalamic-pituitary axis suppression, cutaneous atrophy, striae, rosacea, and telangiectasia. Upon follow-up, patients with moderate to severe disease are usually transitioned to steroid-sparing regimens that include emollients, topical calcineurin inhibitors, and maintenance with twice-weekly TCS. Patients whose disease is not stable after the prehydration clearance regimen and appropriate maintenance therapy are candidates for phototherapy or use of systemic immunosuppressives.
In conclusion, prehydration followed by TCS therapy seems to be a highly effective regimen that achieves rapid control of moderate to severe disease, even in patients who have required systemic therapy. This technique followed by a 1-week to 2-week follow-up visit achieves clearance in most patients, which then allows for the initiation of steroid-sparing maintenance therapy.
